Publications
Detailed Information
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Siyeon | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Cho, Sung-Yup | - |
dc.contributor.author | Kim, Soyeon | - |
dc.contributor.author | Oh, Yumi | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2021-01-31T08:06:24Z | - |
dc.date.available | 2021-01-31T08:06:24Z | - |
dc.date.created | 2020-12-08 | - |
dc.date.created | 2020-12-08 | - |
dc.date.created | 2020-12-08 | - |
dc.date.created | 2020-12-08 | - |
dc.date.created | 2020-12-08 | - |
dc.date.created | 2020-12-08 | - |
dc.date.issued | 2020-12-28 | - |
dc.identifier.citation | Cancer Letters, Vol.495, pp.135-144 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.other | 118788 | - |
dc.identifier.uri | https://hdl.handle.net/10371/171807 | - |
dc.description.abstract | NRAS mutation is rarely observed in non-small cell lung cancer (NSCLC) patients, and there are no approved treatments for NRAS-mutant NSCLC. Here, we evaluated the effect of pan-RAF inhibitors on human NRAS-mutant NSCLC cell lines and performed high-throughput screening using human kinome small interfering (si) RNA or CRISPR/Cas9 libraries to identify new targets for combination NSCLC treatment. Our results indicate that human NRAS-mutant NSCLC cells are moderately sensitive to pan-RAF inhibitors. High-throughput kinome screenings further showed that G2/M arrest, particularly following knockdown of polo-like kinase 1 (PLK1), can inhibit the growth of human NRAS-mutant NSCLC cells and those treated with the type II pan-RAF inhibitor LXH254. In addition, treatment with volasertib plus LXH254, resulting in dual blockade of PLK1 and pan-RAF, was found to be more effective than LXH254 monotherapy for inhibiting long-term cell viability, suggesting that this combination therapeutic strategy may lead to promising results in the clinic. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 조성엽 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1016/j.canlet.2020.09.018 | - |
dc.citation.journaltitle | Cancer Letters | - |
dc.identifier.wosid | 000590212800003 | - |
dc.identifier.scopusid | 2-s2.0-85091652639 | - |
dc.citation.endpage | 144 | - |
dc.citation.startpage | 135 | - |
dc.citation.volume | 495 | - |
dc.identifier.sci | 000590212800003 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Cho, Sung-Yup | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | GENOME | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordPlus | PLK1 | - |
dc.subject.keywordPlus | MEK | - |
dc.subject.keywordAuthor | NRAS-mutant lung cancer | - |
dc.subject.keywordAuthor | High-throughput screening | - |
dc.subject.keywordAuthor | Pan-RAF inhibitor | - |
dc.subject.keywordAuthor | PLK1 inhibitor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.